[HTML][HTML] Visceral leishmaniasis: epidemiology, diagnosis, and treatment regimens in different geographical areas with a focus on pediatrics

S Scarpini, A Dondi, C Totaro, C Biagi, F Melchionda… - Microorganisms, 2022 - mdpi.com
Visceral Leishmaniasis (VL) is a vector-borne disease caused by an intracellular protozoa of
the genus Leishmania that can be lethal if not treated. VL is caused by Leishmania donovani …

[HTML][HTML] Visceral leishmaniasis: recent advances in diagnostics and treatment regimens

J van Griensven, E Diro - Infectious Disease Clinics of North America, 2019 - Elsevier
Visceral leishmaniasis (VL) is a disseminated protozoan infection caused by Leishmania
donovani and Leishmania infantum. 1 Exceptionally, dermatotropic species can visceralize …

Leishmaniasis diagnosis: an update on the use of parasitological, immunological and molecular methods

S Thakur, J Joshi, S Kaur - Journal of Parasitic Diseases, 2020 - Springer
Diagnosis of leishmaniasis has always been a major challenge as its clinical features
resemble some other commonly occurring diseases such as tuberculosis, typhoid, and …

Developments in diagnosis of visceral leishmaniasis in the elimination era

OP Singh, S Sundar - Journal of parasitology research, 2015 - Wiley Online Library
Visceral leishmaniasis (VL) is the most devastating parasitic infection worldwide causing
high morbidity and mortality. Clinical presentation of VL ranges from asymptomatic or …

Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects

SA Ejazi, N Ali - Expert review of anti-infective therapy, 2013 - Taylor & Francis
Human visceral leishmaniasis (VL) continues to be a life-threatening neglected tropical
disease, with close to 200 million people at risk of infection globally. Epidemics and …

The immune response in canine and human leishmaniasis and how this influences the diagnosis-a review and assessment of recent research

L Ivănescu, BL Andronic… - Frontiers in cellular …, 2023 - frontiersin.org
Leishmaniasis is a widespread but still underdiagnosed parasitic disease that affects both
humans and animals. There are at least 20 pathogenic species of Leishmania, most of them …

Evaluation of Blood Agar Microtiter Plates for Culturing Leishmania Parasites To Titrate Parasite Burden in Spleen and Peripheral Blood of Patients with Visceral …

R Maurya, S Mehrotra, VK Prajapati… - Journal of clinical …, 2010 - journals.asm.org
Serial dilution of blood and spleen biopsy specimens, plated on Novy-MacNeal-Nicolle
(NNN) blood agar using microtiter culture plates, is a sensitive and reproducible method for …

Diversity and within-host evolution of Leishmania donovani from visceral leishmaniasis patients with and without HIV coinfection in Northern Ethiopia

SU Franssen, Y Takele, E Adem, MJ Sanders, I Müller… - MBio, 2021 - journals.asm.org
Visceral leishmaniasis (VL) is a fatal disease and a growing public health problem in East
Africa, where Ethiopia has one of the highest VL burdens. The largest focus of VL in Ethiopia …

Tocilizumab as an adjuvant therapy for hemophagocytic lymphohistiocytosis associated with visceral leishmaniasis

R Rios-Fernández, JL Callejas-Rubio… - American journal of …, 2016 - journals.lww.com
Leishmaniasis is important as a cause of hemophagocytic lymphohistiocytosis (HLH) and
must be considered and excluded in patients with HLH because it can cause severe or even …

[PDF][PDF] Visceral leishmaniasis: Epidemiology, diagnosis, and treatment regimens in different geographical areas with a focus on pediatrics. Microorganisms. 2022; 10 …

S Scarpini, A Dondi, C Totaro, C Biagi… - DOI: https://doi. org …, 2022 - academia.edu
Visceral Leishmaniasis (VL) is a vector-borne disease caused by an intracellular protozoa of
the genus Leishmania that can be lethal if not treated. VL is caused by Leishmania donovani …